Orthofix (OFIX) Q2 FY26 earnings call

Orthofix demonstrated tangible operational progress in Q2 FY26, achieving 5% pro forma constant currency net sales growth driven by strong performance in Global Limb Reconstruction and Spine Fixation. While the restoration of Medicare reimbursement and stabilization in Biologics are positive indicators, the company faces ongoing challenges with smaller U.S. spine distributors, leading to a more conservative full-year outlook. Management remains focused on improving commercial productivity and disciplined capital allocation for long-term value creation.